Optibiotix Health Share Discussion Threads

[rafboy] 23/3/2017 10:12

Sounds like all information will be released on the day of listing. SOH has indicated that he would like to see shareholders in Opti own shares in the demerged company. We just have to wait for the details of this to be published. Not long until the 5th of April.

[someuwin] 23/3/2017 10:03

Surely they've got to publish an Admission Document before listing?

Who's going to buy all the IPO shares if they're not being offered to PI's?

[elrico] 23/3/2017 09:57

SOH confirmed AIM rules prevent any more details before listing.
TW confirmed I had my sums right on the 30% being used for the IPO...It's about the only thing I did get right on that front.

[jestercat2] 23/3/2017 09:42

Elrico - why do you say that? Are you implying we won't be able to take part in the Skin IPO?

[elrico] 23/3/2017 09:31

We won't be getting any more info until listing.

[shazbo] 23/3/2017 09:28

I just can't believe we've got so little information SO close to listing. I don't know whether to plough what I have into Opti hoping we'll get some free/discounted shares depending on our Opti holding or should I hold it back to buy Skin when we list? Decisions decisions.

[owenmo] 23/3/2017 09:18

Waiting game maybe, but I'd be be buying rather than selling in the inter-regnum, wouldn't I?

[rafboy] 23/3/2017 09:09

Looks like we are in a waiting mode for news on the terms of the demerger etc. Have to say I have great faith in SOH as for me he has delivered and I look to the future with great optimism.

[someuwin] 23/3/2017 08:49

8 trading days to go until SKIN listing.

Should be getting more details between now and then.

[michaelamouse] 23/3/2017 08:00

fathenry seems a nice fellow, his my new boyfriend



















































still, got soft spt for you Michael xxxxx

[michaelamouse] 23/3/2017 07:57

but Darling ,i still love you so much




















































































sweet dreams xxxx

[michaelamouse] 23/3/2017 07:56

So solly, you did not git it, mine is egg fried lice with chapati and a 87 with 101, tank u jelly much



1039 1 0
fathenry
23 Mar '17 - 07:37 - 1035 of 1035 0 0 Edit
fathenry
23 Mar '17 - 07:37 - 1034 of 1034 0 0 Edit
Optibiotix (OPTI) has announced - not before time we might note- that the demerger of its 52% unit Skinbiotherapeutics and its own AIM listing is underway. I should cocoa. Book building is cracking ahead on the Skinbiotix IPO. Optibiotix currently has an adjusted 52% of Skinbiotherapeutics.

SkinBiotix®, is a proprietary technology platform based on microbiome research, comprises extracts of probiotic bacteria for application to the skin. There are published proof of principle research on SkinBiotix® in models of skin shows improvement of skin barrier function, protection against Staphylococcus aureus infection and regeneration. There are three development programmes in place - cosmetic (sensitive skin), healthcare-acquired infections (HCAIs) and eczema. The business strategy is to bring programmes through proof of concept (human) trials and then seek early stage partnering; lead cosmetic application targeted to be ready for commercialisation in 2018.

But Skinbiotherapeutics needs some cash to do that. Hence the IPO. As we understand it post the fund raise, Skinbiotherapeutics will be cashed up with anough dosh to take it through to commercialisation and Optibiotix will still own a loan note adjusted c44% of the equity.

At some stage Optibiotix will distribute those shares to we lucky shareholders in Optibiotix and since we do not know the record date on that distribution folks would be barking mad to sell. Optibiotix thus becomes doubly exciting. Not only will it be announcing more big news soon on commercialising its products but we now have a similar process likely to happen with Skinbiotherapeutics. Game on!

The shares have responded by moving ahead to 80p-84p. We repeatedly urged you to buy more, and average down, in the 60s and 70s and hope you took our advice. The stance is now VERY STRONG HOLD as we are through that 80p Limit Buying Price.

But Hold on dear friends hold on as these shares will be pushing through 100p far sooner than folks think. The market is yet to appreciate how massive this demerger will be and also what other news Optibiotix itself will be serving up over the coming weeks.

Hang on tight this is going to be exciting and soon

[fathenry] 23/3/2017 07:39

sorry, my finger seems to have got stuck

[fathenry] 23/3/2017 07:39

fathenry
23 Mar '17 - 07:38 - 1036 of 1036 0 0 Edit
fathenry
23 Mar '17 - 07:37 - 1035 of 1035 0 0 Edit
fathenry
23 Mar '17 - 07:37 - 1034 of 1034 0 0 Edit
Optibiotix (OPTI) has announced - not before time we might note- that the demerger of its 52% unit Skinbiotherapeutics and its own AIM listing is underway. I should cocoa. Book building is cracking ahead on the Skinbiotix IPO. Optibiotix currently has an adjusted 52% of Skinbiotherapeutics.

SkinBiotix®, is a proprietary technology platform based on microbiome research, comprises extracts of probiotic bacteria for application to the skin. There are published proof of principle research on SkinBiotix® in models of skin shows improvement of skin barrier function, protection against Staphylococcus aureus infection and regeneration. There are three development programmes in place - cosmetic (sensitive skin), healthcare-acquired infections (HCAIs) and eczema. The business strategy is to bring programmes through proof of concept (human) trials and then seek early stage partnering; lead cosmetic application targeted to be ready for commercialisation in 2018.

But Skinbiotherapeutics needs some cash to do that. Hence the IPO. As we understand it post the fund raise, Skinbiotherapeutics will be cashed up with anough dosh to take it through to commercialisation and Optibiotix will still own a loan note adjusted c44% of the equity.

At some stage Optibiotix will distribute those shares to we lucky shareholders in Optibiotix and since we do not know the record date on that distribution folks would be barking mad to sell. Optibiotix thus becomes doubly exciting. Not only will it be announcing more big news soon on commercialising its products but we now have a similar process likely to happen with Skinbiotherapeutics. Game on!

The shares have responded by moving ahead to 80p-84p. We repeatedly urged you to buy more, and average down, in the 60s and 70s and hope you took our advice. The stance is now VERY STRONG HOLD as we are through that 80p Limit Buying Price.

But Hold on dear friends hold on as these shares will be pushing through 100p far sooner than folks think. The market is yet to appreciate how massive this demerger will be and also what other news Optibiotix itself will be serving up over the coming weeks.

Hang on tight this is going to be exciting and soon!

[fathenry] 23/3/2017 07:38

fathenry
23 Mar '17 - 07:37 - 1035 of 1035 0 0 Edit
fathenry
23 Mar '17 - 07:37 - 1034 of 1034 0 0 Edit
Optibiotix (OPTI) has announced - not before time we might note- that the demerger of its 52% unit Skinbiotherapeutics and its own AIM listing is underway. I should cocoa. Book building is cracking ahead on the Skinbiotix IPO. Optibiotix currently has an adjusted 52% of Skinbiotherapeutics.

SkinBiotix®, is a proprietary technology platform based on microbiome research, comprises extracts of probiotic bacteria for application to the skin. There are published proof of principle research on SkinBiotix® in models of skin shows improvement of skin barrier function, protection against Staphylococcus aureus infection and regeneration. There are three development programmes in place - cosmetic (sensitive skin), healthcare-acquired infections (HCAIs) and eczema. The business strategy is to bring programmes through proof of concept (human) trials and then seek early stage partnering; lead cosmetic application targeted to be ready for commercialisation in 2018.

But Skinbiotherapeutics needs some cash to do that. Hence the IPO. As we understand it post the fund raise, Skinbiotherapeutics will be cashed up with anough dosh to take it through to commercialisation and Optibiotix will still own a loan note adjusted c44% of the equity.

At some stage Optibiotix will distribute those shares to we lucky shareholders in Optibiotix and since we do not know the record date on that distribution folks would be barking mad to sell. Optibiotix thus becomes doubly exciting. Not only will it be announcing more big news soon on commercialising its products but we now have a similar process likely to happen with Skinbiotherapeutics. Game on!

The shares have responded by moving ahead to 80p-84p. We repeatedly urged you to buy more, and average down, in the 60s and 70s and hope you took our advice. The stance is now VERY STRONG HOLD as we are through that 80p Limit Buying Price.

But Hold on dear friends hold on as these shares will be pushing through 100p far sooner than folks think. The market is yet to appreciate how massive this demerger will be and also what other news Optibiotix itself will be serving up over the coming weeks.

Hang on tight this is going to be exciting and soon!

[fathenry] 23/3/2017 07:37

fathenry
23 Mar '17 - 07:37 - 1034 of 1034 0 0 Edit
Optibiotix (OPTI) has announced - not before time we might note- that the demerger of its 52% unit Skinbiotherapeutics and its own AIM listing is underway. I should cocoa. Book building is cracking ahead on the Skinbiotix IPO. Optibiotix currently has an adjusted 52% of Skinbiotherapeutics.

SkinBiotix®, is a proprietary technology platform based on microbiome research, comprises extracts of probiotic bacteria for application to the skin. There are published proof of principle research on SkinBiotix® in models of skin shows improvement of skin barrier function, protection against Staphylococcus aureus infection and regeneration. There are three development programmes in place - cosmetic (sensitive skin), healthcare-acquired infections (HCAIs) and eczema. The business strategy is to bring programmes through proof of concept (human) trials and then seek early stage partnering; lead cosmetic application targeted to be ready for commercialisation in 2018.

But Skinbiotherapeutics needs some cash to do that. Hence the IPO. As we understand it post the fund raise, Skinbiotherapeutics will be cashed up with anough dosh to take it through to commercialisation and Optibiotix will still own a loan note adjusted c44% of the equity.

At some stage Optibiotix will distribute those shares to we lucky shareholders in Optibiotix and since we do not know the record date on that distribution folks would be barking mad to sell. Optibiotix thus becomes doubly exciting. Not only will it be announcing more big news soon on commercialising its products but we now have a similar process likely to happen with Skinbiotherapeutics. Game on!

The shares have responded by moving ahead to 80p-84p. We repeatedly urged you to buy more, and average down, in the 60s and 70s and hope you took our advice. The stance is now VERY STRONG HOLD as we are through that 80p Limit Buying Price.

But Hold on dear friends hold on as these shares will be pushing through 100p far sooner than folks think. The market is yet to appreciate how massive this demerger will be and also what other news Optibiotix itself will be serving up over the coming weeks.

Hang on tight this is going to be exciting and soon!

[fathenry] 23/3/2017 07:37

Optibiotix (OPTI) has announced - not before time we might note- that the demerger of its 52% unit Skinbiotherapeutics and its own AIM listing is underway. I should cocoa. Book building is cracking ahead on the Skinbiotix IPO. Optibiotix currently has an adjusted 52% of Skinbiotherapeutics.

SkinBiotix®, is a proprietary technology platform based on microbiome research, comprises extracts of probiotic bacteria for application to the skin. There are published proof of principle research on SkinBiotix® in models of skin shows improvement of skin barrier function, protection against Staphylococcus aureus infection and regeneration. There are three development programmes in place - cosmetic (sensitive skin), healthcare-acquired infections (HCAIs) and eczema. The business strategy is to bring programmes through proof of concept (human) trials and then seek early stage partnering; lead cosmetic application targeted to be ready for commercialisation in 2018.

But Skinbiotherapeutics needs some cash to do that. Hence the IPO. As we understand it post the fund raise, Skinbiotherapeutics will be cashed up with anough dosh to take it through to commercialisation and Optibiotix will still own a loan note adjusted c44% of the equity.

At some stage Optibiotix will distribute those shares to we lucky shareholders in Optibiotix and since we do not know the record date on that distribution folks would be barking mad to sell. Optibiotix thus becomes doubly exciting. Not only will it be announcing more big news soon on commercialising its products but we now have a similar process likely to happen with Skinbiotherapeutics. Game on!

The shares have responded by moving ahead to 80p-84p. We repeatedly urged you to buy more, and average down, in the 60s and 70s and hope you took our advice. The stance is now VERY STRONG HOLD as we are through that 80p Limit Buying Price.

But Hold on dear friends hold on as these shares will be pushing through 100p far sooner than folks think. The market is yet to appreciate how massive this demerger will be and also what other news Optibiotix itself will be serving up over the coming weeks.

Hang on tight this is going to be exciting and soon!

[marnewton] 22/3/2017 23:43

Not quite a confirmed change of trend by my rather pedantic standards, but close.

Indeed, other charts, such as ADVFN's, would have 81.00p as the breakout/trend change; achieved today on a two day closing basis. Other chartists prefer closing prices, rather than intraday, as their criterion...so yesterday was the day.

Here's the chart, you decide.

(Indicators a bit toppy.)


Log scale daily candlestick chart:

[shrewdmole] 22/3/2017 23:31

I've only just managed to sit down and catch up with today's action and posts.

We are a fickle group of long term holders aren't we!

Look at the trades today, look at the Dow last night and work back again through the published trades.

Other comments from today about people cashing in that bought in the 60's is a possible but really? Opti on fundamentals was overvalued in the 60's. You either believe this is the biggest breakthrough in human health or you don't (I mean the microbiome not Opti) and if you do then Opti is in a leading position and soh has been registering every strain or mutation of a strain he can to protect his and our interests.

For me today it was a transition, the smaller sells and the delayed buys. Expect more tomorrow too.

The serious money is entering and we've all been hoping for that.

Some of it is large short term trades looking for £1 but I'm here for the long run and hope soh sees it through rather than sell.

Sm

[elrico] 22/3/2017 14:03

I think I'll have to crack on with work, I am clearly having issue multi tasking today.Catch you all later.

[elrico] 22/3/2017 13:44

ODR - It's a point I have made. The fact OPTI have chosen now, ahead of Vitafood expo suggests to me they are using the impending multi LP-LDL commercial launch as a springboard for SKIN due to the expected change in sentiment brought about by renewed confidence in the corporate strategy. My only concern is for PI expectations of P&G being named as the first commercial partner launching LP-LDL via Vitafood expo. SOH has already stated he has plans for a stateside visit later. OPTI is sharing a stand with Italy's Nutrilinea, as has been pointed out by other eagle eyed PI's. While Wallbroke deny the conspiracy theories, there is no denying neither company are strapped for cash they need to share the costs of a stand, while keen observers will have noticed Nutrilinea have their own cholesterol range of products. Coincidence? We don't have long to find out.

[rafboy] 22/3/2017 13:37

Assuming you are correct, how much of a discount is usual when deciding what price existing shareholders can purchase shares at the IPO?

P.S. I know the answer is how long is a piece of string but would welcome any views on this.

[someuwin] 22/3/2017 13:36

2,000,000 shares at 10p a share = £200,000.

[elrico] 22/3/2017 13:18

As far as I can calculate (I'm no expert), based on 30% of the issued share capital being used to raise funds for SKIN, I THINK this equates to 2,000,000 new shares. I expect SKIN will opt to raise somewhere between £2 - £3m, c£2.6m net expenses, which equates to 50-100 per share. I have suggested this price range to a number of people over the last few months. I know I am not the only one to come to the same calculations, so I know I am in good company. We could be wrong of course.

edit senior moment. The only equation I got right was the 30% and that is dependant of the loan conversion ;-)

Thank for pointing out my error someuwin.